No Data
Express News | Spero Therapeutics Presents In Vitro Data At IDWeek 2024 Showing SPR719 Has Low Propensity For Resistance Development In NTM-PD MAC Strains, Highlighting SPR720's Potential For Prolonged Combination Regimens
Promising Clinical Developments Underpin Buy Rating for Spero Therapeutics
Spero Therapeutics Phase 1 Trial of Lung Disease Treatment Backs Further Assessment
Spero Therapeutics Announces Publication of SPR719 Trial Data
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
Express News | Spero Therapeutics Publishes SPR720 Phase 1 Lung Exposure Data In Antimicrobial Agents And Chemotherapy